Project Description

antiretrovirals PATA

Quantification and Budgeting for Rapid and Sustainable Access to New Pediatric Antiretroviral Therapies

To improve health and save lives, children diagnosed with HIV need immediate and sustainable access to child-friendly formulations of antiretrovirals (ARVs) that are safe, effective, affordable, and palatable. The World Health Organization (WHO) recommends a preferred first-line treatment of Raltegravir-based (RAL) regimens for neonates, and dolutegravir-based (DTG) regimens for children for whom approved DTG dosing is available.